Telomir Pharmaceuticals Inc (TELO)

Currency in USD
0.3640
-0.0758(-17.24%)
Closed·
0.3730+0.0090(+2.47%)
·
Advertisement
Trading near 52-week Low
Earnings results expected in 0 days
TELO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.35300.4371
52 wk Range
0.35301.5800
Key Statistics
Prev. Close
0.364
Open
0.43
Day's Range
0.353-0.4371
52 wk Range
0.353-1.58
Volume
255.92K
Average Volume (3m)
125.37K
1-Year Change
-71.5625%
Book Value / Share
0.064
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TELO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.0000
Upside
+998.90%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 4.0000
(+998.90% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Buy4.00+998.90%-New Coverage17/09/2026
Rodman & Renshaw
Buy8.00+2,097.80%-New Coverage13/01/2026

Earnings

Latest Release
13/08/2026
EPS / Forecast
-0.79 / -0.04
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare TELO to Peers and Sector

Metrics to compare
TELO
Peers
Sector
Relationship
P/E Ratio
−0.5x−7.1x−0.2x
PEG Ratio
0.00−0.170.00
Price/Book
6.1x2.9x2.6x
Price / LTM Sales
-6.6x2.6x
Upside (Analyst Target)
-269.0%76.9%
Fair Value Upside
Unlock18.2%14.9%Unlock

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson’s disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer’s disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.33M3.16%848.69K
Other Institutional Investors
18.39M24.97%6.70M
Public Companies & Retail Investors
52.95M71.87%19.27M
Total
73.68M100.00%26.82M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Bayshore Trust18.91%13,934,0715,072
MIRA Pharmaceuticals, Inc.4.78%3,521,1271,282

People Also Watch

0.920
RFL
+2.22%
4.300
CXDO
-7.13%
170.31
VSEC
-5.70%
13.620
LYTS
-4.22%
20.120
LINC
-7.71%

FAQ

What Is the Telomir Pharmaceuticals (NASDAQ: TELO) Share Price Today?

The Telomir Pharmaceuticals stock price today is 0.3640 USD.

What Stock Exchange Does Telomir Pharmaceuticals (TELO) Trade On?

Telomir Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Telomir Pharmaceuticals?

The stock symbol (also called a 'ticker') for Telomir Pharmaceuticals is "TELO."

What Is the Current Telomir Pharmaceuticals Market Capitalisation?

As of today, Telomir Pharmaceuticals (NASDAQ: TELO) market cap is 32.4000M USD.

What Is Telomir Pharmaceuticals's (TELO) Earnings Per Share (TTM)?

The Telomir Pharmaceuticals EPS is currently -1.04 (Trailing Twelve Months).

When Is the Next Telomir Pharmaceuticals Earnings Date?

Telomir Pharmaceuticals's next earnings report will be released on 02/12/2026.

Is TELO a Buy or Sell From a Technical Analyst Perspective?

Based on today's Telomir Pharmaceuticals moving averages and other technical indicators, the daily buy/sell signal for TELO stock is Strong Sell.

How Many Times Has Telomir Pharmaceuticals Stock Split?

Telomir Pharmaceuticals has split 0 times. (See the TELO stock split history page for full effective split date and price information.)

What is the current trading status of Telomir Pharmaceuticals (NASDAQ: TELO)?

As of 21/11/2026, Telomir Pharmaceuticals (TELO) is trading at a share price of 0.3640 USD, with a previous close of 0.3640 USD. The stock has fluctuated within a day range of 0.3530 USD to 0.4371 USD, while its 52-week range spans from 0.3530 USD to 1.5800 USD.

What Is Telomir Pharmaceuticals (TELO) Price Target According to Analysts?

The average 12-month price target for Telomir Pharmaceuticals is 4.0000 USD, with a high estimate of 4 USD and a low estimate of 4 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +998.90% Upside potential.

What Is the TELO Premarket Price?

TELO's last pre-market stock price is 0.4397 USD. The pre-market share volume is 510.0000, and the stock has decreased by -0.0001, or -0.0200%.

What Is the TELO After Hours Price?

TELO's last after hours stock price is 0.3730 USD, the stock has decreased by 0.0090, or 2.4700%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.